Seaport Therapeutics

PureTech and Seaport Report Positive GlyphAgo Phase 1 Data

BOSTON, June 8, 2026 PureTech Health and its Founded Entity Seaport Therapeutics announced positive results from the multiple-ascending dose...

By cGxPwire Editor
June 10, 2026

Bio-Pharma

PureTech, Seaport Advance GlyphAllo in Depression Therapy

BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...

By cGxPwire Editor
March 26, 2026

Bio-Pharma

Meta-Analysis Reveals Drivers of Placebo Response in GAD

BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...

By cGxPwire Editor
February 20, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Seaport Therapeutics

PureTech and Seaport Report Positive GlyphAgo Phase 1 Data

PureTech, Seaport Advance GlyphAllo in Depression Therapy

Meta-Analysis Reveals Drivers of Placebo Response in GAD